The Kulay Kalingka Study was launched at the Wiradjuri Condobolin Corporation in July, 2023. Watch our video “Shades of resilience: Unveiling Kulay Kalingka” below to learn more about our study.
The Kulay Kalingka Study arose from Aboriginal and Torres Strait Islander community needs, to better understand cancer attitudes, beliefs and experiences and from calls for the inclusion of Aboriginal and Torres Strait Islander patients, families and communities in cancer research. Additionally, the Study arose from a call from Cancer Australia to improve cancer outcomes for Aboriginal and Torres Strait Islander peoples, including across cancer prevention, screening and early detection, diagnosis and treatment, palliative care and survivorship, and their corresponding service areas.
The Kulay Kalingka Study has ethics approval from AIATSIS (reference #EO324-20220414) and the Australian National University (reference #2022/465). Where required, data custodian approvals and additional ethics approvals will be obtained.
Aboriginal and Torres Strait Islander peoples are involved in all stages of the project, from conception, development and survey testing through to analysis and dissemination.